CVA Family Office’s Guardant Health GH Stock Holding History

CVA Family Office’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.6K	Sell	84 -2	-2%	-$218	﹤0.01%	960
2026 Q1	$7.94K	Buy	86 +81	+1,620%	+$8.13K	﹤0.01%	1067
2025 Q4	$511	Buy	+5	New	+$447	﹤0.01%	1225
2021 Q3	–	Sell	-16	Closed	-$2K	–	554
2021 Q2	$2K	Buy	+16	New	+$2.15K	﹤0.01%	879

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CVA Family Office's GH Position: Q2 2026 in Review

CVA Family Office reduced its Guardant Health (GH) stake by 2.3% in Q2 2026, selling an estimated $218 and leaving 84 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #960.

CVA Family Office first reported a position in GH in Q2 2021 and has held it in 4 quarters since. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

CVA Family Office held 84 shares of Guardant Health worth $12.6K as of Q2 2026.
CVA Family Office sold 2 Guardant Health shares in Q2 2026, an estimated $218.
Guardant Health made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #960 holding.
CVA Family Office first reported a position in Guardant Health in Q2 2021 and has held it in 4 quarters since.
597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.